Inflexion Private Equity has announced that it has agreed to acquire Pharmaspectra, a global provider of medical affairs data to the pharmaceutical and biotech industry. The investment is being made by Inflexion Enterprise Fund IV, Inflexion’s dedicated lower mid‐market fund.
Founded in 2005, Pharmaspectra is the leader in providing scientific dissemination data and analytics to the pharmaceutical industry. Pharmaspectra’s data is utilised by seven of the world’s top 10 pharmaceutical companies. The firm has offices in the UK, US, Switzerland, and India.
With Inflexion’s backing, Pharmaspectra will be expanding its global footprint in the key markets – US, Europe and Asia and accelerating new product development.
Jez Moulding, CEO at Pharmaspectra, commented: “Having created a market-leading product, we see the opportunity to grow further as regulatory changes make data even more crucial for research, development and commercialisation. We believe there is further for us to go with Inflexion behind us, given their proven track record in helping businesses invest in sales and product development as well as digital enhancement.”
Simon Turner, Managing Partner at Inflexion, commented: “Pharmaspectra has amassed the world’s largest collection of medical science globally and made it available to a market increasingly looking for data-driven analytical insights to inform their strategic decisions. This has made the company an indispensable partner to its clients, who stand to benefit as the business enhances its technology to provide an enlarged and improved offering. We look forward to working closely with Jez and the whole team as the company enters the next stage of its growth and development.”
This investment was made by affiliated funds advised by Inflexion Private Equity Partners LLP.